Development and Epitope Mapping of Seven Mouse Anti-Human Coagulation Factor XIII-B Subunit Monoclonal Antibodies.

Autor: Osaki T; Department of Molecular Patho-Biochemistry and Patho-Biology, School of Medicine, Yamagata University, Yamagata, Japan.; The Japanese Collaborative Research Group (JCRG) on Autoimmune Acquired Coagulation Factor Deficiencies Supported by the Japanese Ministry of Health, Labor and Welfare (MHLW), Yamagata University School of Medicine, Yamagata, Japan.; Department of Public Health and Hygiene, Yamagata University Graduate School of Medical Science, Yamagata, Japan., Magari Y; Q-may Laboratory Corporation, Oita, Japan., Souri M; Department of Molecular Patho-Biochemistry and Patho-Biology, School of Medicine, Yamagata University, Yamagata, Japan.; The Japanese Collaborative Research Group (JCRG) on Autoimmune Acquired Coagulation Factor Deficiencies Supported by the Japanese Ministry of Health, Labor and Welfare (MHLW), Yamagata University School of Medicine, Yamagata, Japan.; Department of Public Health and Hygiene, Yamagata University Graduate School of Medical Science, Yamagata, Japan., Ichinose A; Department of Molecular Patho-Biochemistry and Patho-Biology, School of Medicine, Yamagata University, Yamagata, Japan.; The Japanese Collaborative Research Group (JCRG) on Autoimmune Acquired Coagulation Factor Deficiencies Supported by the Japanese Ministry of Health, Labor and Welfare (MHLW), Yamagata University School of Medicine, Yamagata, Japan.
Jazyk: angličtina
Zdroj: Monoclonal antibodies in immunodiagnosis and immunotherapy [Monoclon Antib Immunodiagn Immunother] 2024 Oct; Vol. 43 (5), pp. 135-143. Date of Electronic Publication: 2024 Sep 25.
DOI: 10.1089/mab.2024.0016
Abstrakt: Coagulation factor XIII (FXIII) is an enzyme that strengthens hemostatic clots, and its deficiency can cause life-threatening bleeding. We immunized mice with human plasma-derived FXIII to generate monoclonal antibodies (mAbs) against the B subunit (FXIII-B), which stabilizes the A subunit (FXIII-A) of FXIII, and analyzed their properties. The epitopes of the seven mouse antihuman FXIII-B mAbs obtained were found to be the 3rd, 5th, 6th, 9th, and 10th Sushi domains. One of these mAbs, mAb 5-6C, recognized the 10th Sushi domain and inhibited the fibrin cross-linking reaction without affecting the amine incorporation activity of FXIII. We previously reported that the 10th Sushi domain is the site where FXIII-B binds to fibrin and functions to bring FXIII-A closer to the substrate fibrin. Except for mAb 5-6C, mouse mAbs with high yields were used to measure the amount of FXIII-B antigen by an immunochromatography test (ICT), which showed a high correlation with enzyme-linked immunosorbent assay-obtained results. In addition, we developed a prototype ICT to detect anti-FXIII-B autoantibodies using mAb 1-3C, which showed good results in measuring the amount of FXIII-B antigen. Thus, mouse mAbs may be useful for clinical applications. mAb 5-6C targeting the 10th Sushi domain may also be useful for inhibiting thrombosis progression when humanized as antibody medicines.
Databáze: MEDLINE